tbuckley/cabot-search huggingface dataset:
Abstract P1-14-04: Clinical Outcomes of Brain Metastasis by Lapatinib (L) and Capecitabine (C) in an Open-Label Expanded Access Study among Korean Patients with HER2 Positive Metastatic Breast Cancer
Authors: J Ro, S Park, S-B Kim, T-Y Kim, Y-H Im, SY Rha, JS Chung, H Moon, S. Santillana
Journal: Cancer Research (2010)

Abstract Background: The L-Expanded Access Program (LEAP) was designed to provide access to L/C for HER2+ patients (pts) who previously received anthracycline, taxane, and trastuzumab. In earlier registration trial, CNS metastases occurred in fewer women receiving L/C therapy compared with C alone. Although L therapy has shown efficacy in brain metastasis (BM), it has not been well elucidated in relationship with the outcomes of systemic disease. Patients and methods : Enrollment in LEAP lasted between Jan. 2007 and Apr. 2008 at 6 centers in Korea. Exploratory analysis on clinical outcomes of brain metastasis was performed. Results: Total 187 pts enrolled in LEAP. The median treatment duration of all pts was 19.0 weeks (range, 1.4 — 146.9). The median progression free survival and overall survival (OS) of all pts were 20.0 (95% confidence interval [CI]= 18.6-24.0) and 60.0 (95% CI= 50.3-72.7) weeks, respectively. All patients received prior trastuzumab therapy, and 48.7% received prior capecitabine. Among 58 enrolled pts who had BM diagnosed before start L/C therapy, 55 pts were included for the analysis excluding 3 pts (1-consent withdrawal and 2-&amp;lt;3 weeks trial). Fifteen pts had single BM. Majority were HER2 IHC 3+ or FISH +, and 48% were both ER/PR-. Prior to EAP enrollment, 35 pts underwent whole brain radiation, 10 pts SRS or gamma knife, 3 pts local excision, 1 pt had leptomeningeal disease only receiving intrathecal therapy, and 6 pts did not receive local CNS therapy. Four pts underwent more than one modality of local CNS therapy. Of 50 pts evaluable for response, 9.1%, achieved or remained CR; 45.5% had some degree of shrinkage of BM; 14.5%, no change (SD) ≥6mo; 7.3%, SD &amp;lt;6mo; 14.5% developed PD or recurrence of BM. Median TTP of pts (n=53) with BM on L/C therapy was 30.7 weeks (95% CI=25.0-35.1) and median OS (n=55) was 53.1 weeks (95% CI= 42.3-78.0). From the multivariate analysis, TTP of BM was significantly associated with response of BM (HR, 20.3, 95% CI=7.3-56.0, P&amp;lt;0.001). OS of pts with BM was significantly longer with tumors of ER or PR+ status (HR, 3.10, 95% CI=1.55-6.19, p=0.0014), and who responded in systemic disease and brain (HR, 4.5, 95% CI= 2.2-9.2, P&amp;lt;0.0001). Of remaining 129 pts, 8 pts (6.2%) developed new BM on EAP. Conclusion: Overall survival of patients with brain metastasis who received lapatinib plus capecitabine was prolonged specifically in responders of both brain and extracranial disease. Patients with hormone receptor positive tumors had longer survival compared with those of hormone receptor negative disease. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-14-04.
Zoster of the Tympanic Membrane
Authors: Kenta Watanabe, Maki Funaki
Journal: New England Journal of Medicine (2011)

A 44-year-old man presented with severe right otalgia after an outbreak of a rash on the right side of his face. He had been treated for AML with cord-blood stem-cell transplantation 6 months earlier and had received immunosuppressive therapy with glucocorticoids.
644 COMPARISON BETWEEN THE CONVENTIONAL CRITERION AND THE AKIN CRITERIA IN THE DEFINITION OF ACUTE KIDNEY INJURY IN HOSPITALIZED PATIENTS WITH CIRRHOSIS AND ASCITES
Authors: S. Rosi, S. Piano, F. Morando, A.C. Frigo, S. Fasolato, A. Sticca, A. Romano, M. Cavallin, A. Gatta, P. Angeli
Journal: Journal of Hepatology (2012)
Abstract 3544: The gastric mucosal tissue interleukin-8 mRNA expression level is a promising prognostic marker for prognosis prediction in advanced gastric cancer treatment.
Authors: Bandhuphat Chakrabandhu
Journal: Cancer Research (2013)

Abstract Background : The Interleukin-8 is one of the potent chemokine that plays the major role in cancer inflammatory and vascular growth pathway. We conduct this experiment to determine how difference of its level between non-cancer and cancer location, and its possibility to predict prognosis and result of advance gastric cancer treatment . Method : We collected 309 gastric tissue samples from 129 Thai advance gastric cancer patients during January 2007 to March 2012 . Clinical information was prospective collected on electronic data base. The Interleukin-8 expression levels were detected by relative quantitation RT-PCR method with Taqman probe for Interleukin-8 on 7500 series machine, Applied Biosystem . Test of difference of Mean was done with independent and paired t-test by SPSS version 17th. Test of difference was considered significant by p value ≤0.05. Result : The gastric mucosal tissue IL-8 mRNA expression level was significantly higher in tumor specimen than benign specimen by level of 5469.35 and 565.42 respectively (p =0.13). Its level in diffuse histologic type,metastatic disease and positive lymph node group are higher without significant difference. In subgroup analysis for 50 neo- adjuvant chemotherapy patients, the responder group (partial response and complete response) had a lower IL-8 expression level than non-responder group by the means level of1904.02, 24269.31,respectively (p=0.209). Conclusion : Gastric mucosal tissue IL-8 mRNA expression level was remarkable increased in advance gastric cancer and signet ring cell type. We found that the higher expression level is directly correlated with more advance of histological grading and prognosis of disease treatment. The chemotherapy response rate was poorer in extremely high expression. High interleukin-8 expression could be considered as poor clinical prognostic factor for gastric cancer treatment, and it may be helpful tool to predict the chemotherapy response in future. Citation Format: Bandhuphat Chakrabandhu. The gastric mucosal tissue interleukin-8 mRNA expression level is a promising prognostic marker for prognosis prediction in advanced gastric cancer treatment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3544. doi:10.1158/1538-7445.AM2013-3544
AB0348 Risk of falling is equivalent between patients with rheumatoid arthritis and healthy individuals -the tomorrow study-:
Authors: Y. Sugioka, T. Koike, K. Mamoto, T. Okano, M. Tada, S. Wakitani, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falling. The present study prospectively determines the incidence of falls and their risk factors in patients with RA who participated in the TOMORROW (TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOWer morbidity and mortality; clinical trial registration number: UMIN000003876) study that was started in 2010. <h3>Methods</h3> We evaluated anthropometric parameters, muscle volume, bone density, disease activity, general health status and the occurrence of falls for a period of one year in 202 patients with RA (54% administered with biological agents) and 202 age- and sex-matched healthy volunteers (HV). <h3>Results</h3> Among the patients with RA and HV, 18% and 16% respectively reported one or more falls during the previous year.These values did not significantly differ. After adjusting for risk factors of falls such as a history of falls, age, gender, smoking and BMI, multiple logistic regression analysis identified that a history of falls was the most significant parameter associated with falls (odds ratio: 2.71, p&lt;0.001 Table). The RA group also had lower whole muscle volume (37.2 vs. 39.6 kg; p=0.001), leg bone mineral density (0.967 vs. 1.031 mg/cm<sup>3</sup>; p&lt;0.001) and shorter exercise periods than HV, but none of these were associated with rates of falling. Furthermore, fall risk did not significantly and linearly increase with disease duration, disease activity score and physical status among the patients with RA. <h3>Conclusions</h3> We concluded that the fall rate is not higher in patients with RA than in healthy volunteers and that only a history of falls plays a role in increasing the risk of falls. <h3>Disclosure of Interest</h3> Y. Sugioka: None Declared, T. Koike Grant/Research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, K. Mamoto: None Declared, T. Okano: None Declared, M. Tada: None Declared, S. Wakitani: None Declared, H. Nakamura Grant/Research support from: Chugai Pharmaceutical, Astellas Pharma Inc.,Janssen Pharmaceutica, GlaxoSmithKline, Pfizer Inc. and Daiichi Sankyo, INC., Speakers Bureau: Ono Pharmaceutical
“The map is not the territory”
Authors: Fred L. Bookstein
Journal: Behavioral and Brain Sciences (2014)

Abstract Bentley et al.’s claim that their “map … captures the essence of decision making” (target article, Abstract) is deconstructed and shown to originate in a serious misunderstanding of the role of principal components and statistical graphics in the generation of pattern claims and hypotheses from profile data. Three alternative maps are offered, each with its radiation of further investigations.
Abstract 43: Detection of bladder cancer-associated gene methylation using next-gen bisulfite sequencing.
Authors: Andrew R. Dunn, Shuqiang Li, Cecilia A. Fernandez, Anthony P. Shuber
Journal: Cancer Research (2013)

Abstract DNA methylation profiling of bladder cancer specific gene promoters has been shown to be a sensitive and specific diagnostic tool for early- and late-stage bladder cancer. We have recently shown that a urine-based assay that combines DNA and protein biomarkers can accurately triage patients undergoing evaluation for bladder cancer. As part of this assay, hypermethylation of Twist1 and Nid2 is performed by conventional methylation-specific PCR (cMSP). To increase throughput and lower cost, we have now developed an approach to determine the methylation at single-base resolution of CpG sites using next generation bisulfite sequencing. In addition to Twist1 and Nid2, methylation of the Vimentin promoter, which has been shown to be associated with epithelial to mesenchymal transition (EMT) in bladder cancer, was also evaluated using this technique. To determine the sensitivity of this approach, amplification was performed on control bisulfite converted genomic DNA that was either enzymatically methylated or chemically unmethylated at CpG sites using non-methylation specific PCR. Twist1, Nid2 and Vimentin PCR products were subsequently used as template for emulsion PCR and sequenced using the Ion Torrent PGM. Methylation status was determined by aligning sequencing reads to unmethylated reference sequences. In this assay, 0.4% methylated DNA could be reliably detected in 10 ng of bisulfite converted DNA, more than doubling the sensitivity of the current assay as well as potentially generating a single-base resolution mapping of additional CpG sites not yet quantified for Twist1, Nid2 and Vimentin. The clinical performance of the Next-Gen bisulfite sequencing assays for Twist1, Nid2 and Vimentin is currently being tested using urine samples from patients with bladder cancer as well as from age matched individuals who present with hematuria but who are found to be cancer-free. The technique we have developed could be used to detect other hypermethylated genes in a variety of bodily fluids where percent methylation may be much lower than in tumor tissue samples. Citation Format: Andrew R. Dunn, Shuqiang Li, Cecilia A. Fernandez, Anthony P. Shuber. Detection of bladder cancer-associated gene methylation using next-gen bisulfite sequencing. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 43. doi:10.1158/1538-7445.AM2013-43
P4-10-09: Hormone Replacement Therapy: A Benign Breast Disease's Risk?
Authors: AS Hamy, H Gronier, R Porcher, S Giacchetti, C Cuvier, Roquancourt A De, M Espie
Journal: Cancer Research (2011)

Abstract Background Use of hormone replacement therapy (HRT) has been associated with increased risk of breast cancer. However relations between use of HRT and benign breast lesions remain contradictory (1-3). Our goal was to investigate whether HRT and its duration use are associated with benign breast lesions. Materials &amp; Methods From 2001 to 2007, 2708 patients with a non palpable breast lesion were referred to our breast care center. Radiological abnormalities were screened either by breast ultrasound mammography, or MRI. Of those, 1 329 patients had a biopsy in our Radiology Unit. We focus on the postmenopausal women (n=739). Clinical data including HRT use extent were reported. Patients with previous history of benign breast disease or malignancy were excluded. Results The analysis was performed on 739 patients. Biopsies yielded a benign result in 414 (56%) of them (fibroadenoma n=71, blunt duct adenosis n=94, fibrocystic disease n=92, epithelial hyperplasia n=56, others n=101), high risk lesions in 57 (8%) (atypical ductal hyperplasia n=28, atypical lobular hyperplasia n=19, lobular carcinoma in situ n=10) and malignancy in 268 (36%) (not studied here). For the 471 patients with benign or high risk breast lesion, the median age was 59 years, 80% had at least one pregnancy and 27% had a family history of breast cancer. Among these 471 patients, 47% of them had used an oral contraceptive and 53% of them a HRT, with a mean duration of use of 2 years. The HRT use was not significantly associated with the type of benign or high risk breast disease. No association was observed either between breast disease and duration of HRT (less or more than 7 years respectively).Older age was significantly correlated to atypia or carcinoma (median age at diagnosis 59 y.o in benign lesions, 60 y.o in high risk lesions and 62 y.o in malign lesions, with significant difference) (p&amp;lt;0,0001). Conclusion In this study of postmenopausal women, HRT and its duration use were not associated with the type of benign or high risk breast lesion. Although a lack of statistical power may be invoked to explain the results, we are called to believe that the magnitude of an effect of HRT use is small, if ever it exists. 1. Finkelde DT, Kitchen PR, Hayes PR, McKinlay MR, Henderson MA 2001 Symptomatic benign breast disease and hormone replacement therapy. Breast 10:127–130 2. Gayet A, Esteve J, Seradour B, Piana L, Jacquemier J 2003 Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign. Eur J Cancer 39:1738–1745 3. Rohan TE, Miller AB 1999 Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 8:123–130 Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-10-09.
Catheter Ablation of Accessory Atrioventricular Pathways (Wolff–Parkinson–White Syndrome) by Radiofrequency Current
Authors: W M Jackman, X Z Wang, K J Friday, C A Roman, K P Moulton, K J Beckman, J H McClelland, N Twidale, H A Hazlitt, M I Prior
Journal: New England Journal of Medicine (1991)

Surgical or catheter ablation of accessory pathways by means of high-energy shocks serves as definitive therapy for patients with Wolff–Parkinson–White syndrome but has substantial associated morbidity and mortality. Radiofrequency current, an alternative energy source for ablation, produces smaller lesions without adverse effects remote from the site where current is delivered. We conducted this study to develop catheter techniques for delivering radiofrequency current to reduce morbidity and mortality associated with accessory-pathway ablation.
Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?
Authors: J. L. Grem, B. D. Cheson, S. A. King, B. Leyland-Jones, M. Suffness
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure? Get access Jean L. Grem, Jean L. Grem * 2Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer InstituteBethesda, MD 20892. *Correspondence to: Dr. Jean L. Grem, Executive Plaza North, Room 731, National Institutes of Health, Bethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar Bruce D. Cheson, Bruce D. Cheson 2Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer InstituteBethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar Susan A. King, Susan A. King 2Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer InstituteBethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar Brian Leyland-Jones, Brian Leyland-Jones 2Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer InstituteBethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar Matthew Suffness Matthew Suffness 3the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer InstituteBethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 14, 21 September 1988, Pages 1095–1103, https://doi.org/10.1093/jnci/80.14.1095 Published: 21 September 1988 Article history Received: 28 March 1988 Revision received: 03 June 1988 Accepted: 03 June 1988 Published: 21 September 1988
Abstract 1877: Predictive marker discovery for Sorafenib using patient derived xenograft models of hepatocellular carcinoma
Authors: Juan Zhang, Yanmei Sun, Xiaoming Song, Jie Yang, Jie Cai, Qian Shi, Taiping Chen
Journal: Cancer Research (2012)

Abstract Sorafenib, a multikinase inhibitor targeting vascular endothelial growth factor (VEGF)- mediated angiogenesis and blocking the RAF/extracellular signal regulated kinase (ERK) kinase (MEK)/ERK cascade, is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC). Although it is only used in treating advanced renal cell carcinoma and unresectable HCC, many patients with other malignant diseases as well as patient with resectable HCC may also benefit from this treatment. There is a clear need for predictive markers of Sorafenib to help selecting the patient population that may benefit the most. We set out to discover the predictive markers using patient derived xenograft (PDX) models of HCC. The response to Sorafenib was investigated in 20 PDX subcutaneous models and 6 orthotopic cell line (MHCC97H, HUH-1, HepG2, Hep3B, SK-Hep-1 and PLC/PRF/5) derived xenogrft (CDX) models. 11 out of 20 PDX models (55%), and 4 out of 6 CDX models (67%) achieved significant tumor growth inhibition by the treatment of Sorafenib at the dose range from 25-50 mg/kg in nude mice. Gene expression profile, hotspot mutation detection and copy number variations were analyzed to sift out the molecular signatures that may be predictive of the response to Sorafenib. Genes and pathways such as VEGF, PDGF, FGF, Raf/MAPK/ERK, PTEN/ PI3K/AKT/mTOR, TGF-beta/Wnt, EGFR, IGF and HGF/c-MET, were investigated using methods such as IHC analysis of pretreatment xenograft tissues. Our results indicate that more than half of the resectable HCC may be responsive to Sorafenib treatment, and markers other than the usual targets of Sorafenib may be predictive of this response. This study may shed light on the predictive markers of Sorafenib and help patients that may be mostly benefited from this drug. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1877. doi:1538-7445.AM2012-1877
PREFRONTAL LOBECTOMY (EXCISION OF THE ANTERIOR AREAS OF THE CEREBRUM)
Authors: W. T. PEYTON, H. H. NORAN, E. W. MILLER
Journal: American Journal of Psychiatry (1948)

A new type of psychosurgical technique, namely, prefrontal lobectomy, is described. The advantages of this procedure over prefrontal lobotomy are presented. The results of prefrontal lobectomy are reported in 14 patients with 85.7% showing moderate to marked improvement. This series of cases consisted predominantly of chronic schizophrenia, 11 of the cases being classified as dementia præcox. Moderate to marked improvement followed lobectomy in 82.6% of the latter group of patients. In general, the results for this new psychosurgical procedure compare well with the published reports for prefrontal lobotomy.
Abstract LB-403: Levels of nitric oxide and prostate cancer development in healthy US men enrolled in the Health Professionals Follow-up Study
Authors: Tianying Wu, Yushan Wang, Shuk-Mei Ho, Edward Giovannucci
Journal: Cancer Research (2010)

Abstract Nitric oxide (NO) has a strong impact on cancer development. Experimental studies have reported that, depending on levels, NO has either tumoricidal or tumor-promoting effects. In addition, NO is strongly associated with oxidative and inflammatory pathways, which have been implicated in prostate cancer. In general, maintaining normal-range levels of NO is important for physiological function and may actually have tumoricidal effects. Furthermore, extremely high levels of NO have been found to stimulate prostate tumor growth in rats. However, the relationship between plasma NO level and risk of prostate cancer (PCa) development has not been assessed. NO is difficult to measure directly in large epidemiologic studies. This barrier has hampered the identification of NO-related pathways in cancer development. We have found that plasma levels of nitrite/nitrate, measured as a surrogate marker of NO, are both stable and reproducible within individuals over time. Using a prospective nested case-control design, we identified 600 PCa cases and 600 matched controls from 2000-2004 among men who provided a blood sample in 1993-1995. This study is nested within a blood cohort in the Health Professionals Follow-up Study. We have already measured baseline plasma levels of nitrite/nitrate in 170 cases and 170 controls. The multivariate-adjusted odds ratio of nitrite/nitrate from quintile 2-quintile 4 as compared to quintile 1 are 0.71 (95%CI, 0.24-2.75), 0.20 (95%CI, 0.05-0.75), 0.81 (95%CI, 0.30-2.91), and 1.12 (95%CI, 0.65-2.78), respectively. Our preliminary data suggest that medium levels of nitrite/nitrate maximally reduce the risk of prostate cancer, and that men with high or low levels of nitrite/nitrate may be at elevated risk of prostate cancer. Confirming our results in our remaining samples and other populations may have important implications for prevention of prostate cancer. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-403.